Corrigendum to “Vascular brain-derived neurotrophic factor pathway in rats with adjuvant-induced arthritis: Effect of anti-rheumatic drugs” [Atherosclerosis 274 (July 2018) 77–85]

Martin Pedard (1, 2) , Aurore Quirie (1) , Perle Totoson (3) , Frank Verhoeven (3) , Philippe Garnier (1) , Anne Tessier (1) , Céline Demougeot (3) , Christine Marie (1)

1 CAPS - Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093]
2 Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon)
3 PEPITE - Pathologies et épithéliums : prévention, innovation, traitements, évaluation (UR 4267)

The Authors of the above paper regret that there was an error in the published Abstract section. The correct section is therefore published below (the word ‘lower’ has replaced the word ‘higher’ in the first sentence). Results: Vascular BDNF and full length tropomyosin-related kinase B receptor (TrkB-FL) were lower in AIA than in control rats. These changes coincided with decreased endothelial immunoreactivity in BDNF and pTrkBtyr816 and were disconnected from arthritis score. Among anti-rheumatic drugs, only prednisolone and methotrexate prevented AIA-induced vascular BDNF loss. The effect of AIA on aortic BDNF levels was reversed by an NO donor and reproduced by an NOS inhibitor. Finally, LM22A-4 induced both NO-dependent vasodilation and phosphorylation of endothelial NO synthase at serine 1177.

Domaines: Sciences du Vivant [q-bio]; Médecine humaine et pathologie; Cardiologie et système cardiovasculaire

Martin Pedard, Aurore Quirie, Perle Totoson, Frank Verhoeven, Philippe Garnier, et al.. Corrigendum to “Vascular brain-derived neurotrophic factor pathway in rats with adjuvant-induced arthritis: Effect of anti-rheumatic drugs” [Atherosclerosis 274 (July 2018) 77–85]. Atherosclerosis, 2019, 280, pp.201. ⟨10.1016/j.atherosclerosis.2018.09.036⟩. ⟨hal-02319826⟩